Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Russia provided Iran with list of Israeli energy targets, Ukrainian intelligence finds - 2Three arrested in Paris after attempted bomb attack outside Bank of America
- 3'Wicked: For Good' was filmed at this surreal National Park in Egypt
- 4Vote In favor of Your Favored Sort Of Bevarage
- 54 injured in shooting at North Carolina tree lighting ceremony
- Pick Your Favored kind of salad
- Countdown to Artemis II: What to know about NASA's moon mission
- High Court weighs Assenheim appeal over release of Feldstein interview raw footage
- Careful Living: Embracing the Current Second
- There’s ‘super flu,’ COVID, RSV. Is it going around in SoCal?
- Astronauts head home early after medical issue
- Famous Rough terrain Vehicles for 2024
- Global measles cases drop 71% in 24 years as vaccination coverage improves, WHO says
- Skeleton of famed musketeer possibly found in Dutch church
